DOCSLIB.ORG

International Association of Breath Research Breath Summit 2019 8-11Th September 2019 Conference Programme and Abstracts

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
International Association of Breath Research Breath Summit 2019 8-11Th September 2019 Conference Programme and Abstracts INTERNATIONAL ASSOCIATION OF BREATH RESEARCH BREATH SUMMIT 2019 8-11TH SEPTEMBER 2019 CONFERENCE PROGRAMME AND ABSTRACTS 1 Official Journal of the International Association for Breath Research; Journal of Breath Research is dedicated to all aspects of scientific breath research. The traditional focus is on analysis of volatile compounds and aerosols in exhaled breath for the investigation of exogenous exposures, metabolism, toxicology, health status and the diagnosis of disease and breath odours. The journal also welcomes other breath-related topics. JBR has recently launched two special issues now open for JOURNAL submissions. Most content will be invited by the Guest IMPACT FACTOR Editors, but if you have a paper you would like to be considered for one of these ongoing issues please email the 3.000 journal mailbox at [email protected]. Breath Analysis in Perioperative and Critical Care Medicine Guest Editors Nandor Marczin, Harefield Hospital, UK Simona Cristescu, Radboud University, Nijmegen, The Netherlands Stephen Fowler, The University of Manchester, UK Marcus J Schultz, University of Amsterdam, The Netherlands Optical Spectroscopy for Breath Analysis Guest Editors Simona Cristescu, Radboud University, Nijmegen, The Netherlands Torsten Frosch, Leibniz Institute of Photonic Technology Visit iopscience.org/jbr for more information 2 Table of Contents Sunday 08 September 2019 .................................................................................................. 9 THE TURING EXHIBITION SPACE ......................................................................................... 9 Monday Morning 09 September 2019 ................................................................................. 11 THE TURING EXHIBITION SPACE ....................................................................................... 11 Monday Morning 09 September 2019 ................................................................................. 13 THE STEPHENSON LECTURE ROOM ................................................................................. 13 Monday Afternoon 09 September 2019 ............................................................................. 14 THE TURING EXHIBITION SPACE ....................................................................................... 14 Monday Afternoon 09 September 2019 ............................................................................. 15 THE STEPHENSON LECTURE ROOM ................................................................................. 15 Tuesday Morning 10 SEPTEMBER 2019 ............................................................................. 17 THE TURING EXHIBITION SPACE ....................................................................................... 17 Tuesday Morning 10 SEPTEMBER 2019 ............................................................................. 19 THE STEPHENSON LECTURE ROOM ................................................................................. 19 Tuesday Afternoon 10 SEPTEMBER 2019 ........................................................................... 20 THE TURING EXHIBITION SPACE ....................................................................................... 20 Tuesday Afternoon 10 SEPTEMBER 2019 ........................................................................... 21 THE STEPHENSON LECTURE ROOM ................................................................................. 21 Wednesday 11 SEPTEMBER 2019 ....................................................................................... 23 THE TURING EXHIBITION SPACE ....................................................................................... 23 Sunday 08 September 2019 ................................................................................................ 25 THE TURING EXHIBITION SPACE ....................................................................................... 25 1. PLENARY: VOC Analysis - A Trailblazer In Translational Research? ....... 26 2. PLENARY: Analyzing Volatile Organic Compounds For The Detection Of Colorectal Cancer ...................................................................................... 27 Monday 09 September 2019 ............................................................................................... 29 THE TURING EXHIBITION SPACE ....................................................................................... 29 3. PLENARY: VOCS Related To Systemic Inflammatory Response Syndrome In A Caprine Animal Model ........................................................................ 31 4. HEADLINE: Characterization of VOCs Emitted from Pathogenic Bacteria and Algal Cultures Using SPME-GC-MS: Towards Non-Invasive Diagnostics for Biosecurity and Bioenergy ................................................................... 32 5. Identifying Volatile Biomarkers For A Valley Fever Breath Test .............. 34 6. Identification Of The Most Prevalent Pathogens In Abdominal Sepsis Based On Headspace Analysis Of Volatile Organic Compounds ............ 35 7. HEADLINE: VOC analysis for metabolic monitoring in vitro .................... 36 8. Detection of Mycobacterium avium ssp. paraturberculosis from native samples using VOC analysis and machine learning tools ...................... 37 9. VOC profiles mirror viral-bacterial (co)infections in human cells ........... 38 3 10. PLENARY Beyond PTR - Additional ionization modes in PTR-TOFMS and their use in breath gas analysis ................................................................ 39 11. "Breath Intelligence" - A Portable Handheld System For The Monitoring Of Breath Compounds Related To Metabolism And Oral Hygiene .............. 40 12. Further Evaluation of a Standardized Breath Sampling Device for Off-line Exhaled Breath Analysis ............................................................................ 41 13. HEADLINE: Effect of wood smoke exposure on exhaled breath CO and pulmonary gas exchange parameters ...................................................... 42 14. Efficacy of 13C-breath test as a beacon to locate entrapped casualties in search and rescue missions ..................................................................... 43 15. Identification of a large set of volatile organic compounds characteristic for cystic fibrosis in children ..................................................................... 44 16. Perioperative anesthesia analysis of volatile organic compounds (VOC) in plasma and urine for lung adenocarcinoma and pulmonary granuloma by HS-GC-IMS .................................................................................................. 45 THE STEPHENSON LECTURE ROOM ................................................................................. 47 17. HEADLINE: Direct Detection Of Sub-ppbv Level Of Breath N-Alkanes By Photoelectron Induced O2+ Cation Chemical Ionization Mass Spectrometry .............................................................................................. 48 18. Using Labelled Internal Standards To Improve The Analytical Performance Of Breath Analysis By Needle Trap Micro-Extraction Gas Chromatography- Mass Spectrometry (NTME-GC-MS) .......................................................... 49 19. Development Of An IMS-Based Method For Passenger Control At Airports: A Proof-Of-Concept Study .......................................................................... 50 20. HEADLINE: Automated Thermal Desorption (TD)-SIFT-MS: A New Paradigm for Breath Analysis.................................................................... 51 21. Taking Soft Chemical Ionisation Mass Spectrometry techniques on the “Walk of the World” a breath-taking adventure ...................................... 52 22. Selective and Sensitive Measurement of Trace Exhaled HCN by Acetone- Assisted Negative Photoionization Time-of-flight Mass Spectrometry ... 53 23. ETNO As A Biomarker For Investigating The Effect Of Different OLV Strategies On Lung Injury And Inflammation Response. ........................ 54 24. Stability of FENO50 in a COPD cohort in Sweden over 2-year follow-up 55 25. HEADLINE: A proposed data standard for breath sample data and metadata .................................................................................................... 56 26. Combining field-asymmetric ion mobility spectrometry (FAIMS), Infrared (IR) and luminescence sensing (LS) for artificial breath analysis .......... 57 27. Collection Of Breath Samples For Offline ‘Breathomics’ Mass Spectrometry Analysis Using The ReCIVA® Device In Patients With Acute Breathlessness: A Feasibility Study .......................................................... 58 28. Real-time breath analysis with SESI-HRMS, confounding factors & standardization strategies to initiate multi-center studies ..................... 60 Tuesday 10 SEPTEMBER 2019 ............................................................................................ 61 THE TURING EXHIBITION SPACE ....................................................................................... 61 29. PLENARY Utilizing the US-EPA CompTox Chemicals Dashboard to deliver public access to a Human Volatilome subset of data ............................. 62 4 30. HEADLINE: Standardization procedure for exhaled breath analysis using secondary electrospray ionization mass spectrometry ........................... 63 31. Saliva Screening For Rapid Organophosphate Poisoning Screening: A Case Study With Preliminary Observations And Findings ......................
Load more

Recommended publications
  • Elexacaftor/Tezacaftor/Ivacaftor Elexacaftor 200 Mg, Was Compared to Placebo in a 24-Week Phase III Trial
    EARLY RELEASE : 24 JUNE 2021 NEW DRUGS The triple combination therapy, containing Elexacaftor/tezacaftor/ivacaftor elexacaftor 200 mg, was compared to placebo in a 24-week phase III trial. The 403 patients in Approved indication: cystic fibrosis the trial had an F508del mutation on one allele First published Trikafta (Vertex) and a minimal function mutation on the other. At 24 June 2021 https://doi.org/10.18773/ 100 mg/75 mg/50 mg film-coated tablets baseline their mean percentage of predicted FEV1 was approximately 61%. By four weeks this had austprescr.2021.031 Cystic fibrosis is an autosomal recessive disorder improved by an average of 13.6 percentage points caused by mutations in the genes encoding the in the 200 patients who took the combination. cystic fibrosis transmembrane conductance regulator This change was sustained at week 24 while the (CFTR). There are many possible mutations affecting FEV of patients in the placebo group declined the formation and function of the CFTR protein. 1 slightly. There were 41 pulmonary exacerbations The most common is the F508del mutation. These in the treatment group compared with 113 in the mutations result in defects in the transport of chloride placebo group. Treatment also reduced the sweat ions. This leads to the formation of thick mucus which chloride concentration.2 affects the lungs, pancreas and gut. Another phase III trial studied the combination in In the past decade several drugs have been patients who were homozygous for the F508del developed to enhance the structure and activity of the mutation. This randomised 55 patients to take CFTR protein.
    [Show full text]
  • Retention Indices for Frequently Reported Compounds of Plant Essential Oils
    Retention Indices for Frequently Reported Compounds of Plant Essential Oils V. I. Babushok,a) P. J. Linstrom, and I. G. Zenkevichb) National Institute of Standards and Technology, Gaithersburg, Maryland 20899, USA (Received 1 August 2011; accepted 27 September 2011; published online 29 November 2011) Gas chromatographic retention indices were evaluated for 505 frequently reported plant essential oil components using a large retention index database. Retention data are presented for three types of commonly used stationary phases: dimethyl silicone (nonpolar), dimethyl sili- cone with 5% phenyl groups (slightly polar), and polyethylene glycol (polar) stationary phases. The evaluations are based on the treatment of multiple measurements with the number of data records ranging from about 5 to 800 per compound. Data analysis was limited to temperature programmed conditions. The data reported include the average and median values of retention index with standard deviations and confidence intervals. VC 2011 by the U.S. Secretary of Commerce on behalf of the United States. All rights reserved. [doi:10.1063/1.3653552] Key words: essential oils; gas chromatography; Kova´ts indices; linear indices; retention indices; identification; flavor; olfaction. CONTENTS 1. Introduction The practical applications of plant essential oils are very 1. Introduction................................ 1 diverse. They are used for the production of food, drugs, per- fumes, aromatherapy, and many other applications.1–4 The 2. Retention Indices ........................... 2 need for identification of essential oil components ranges 3. Retention Data Presentation and Discussion . 2 from product quality control to basic research. The identifi- 4. Summary.................................. 45 cation of unknown compounds remains a complex problem, in spite of great progress made in analytical techniques over 5.
    [Show full text]
  • Analysis of Volatile Organic Compounds in Exhaled Breath for Lung Cancer Diagnosis Using a Sensor System
    The University of Manchester Research Analysis of volatile organic compounds in exhaled breath for lung cancer diagnosis using a sensor system DOI: 10.1016/j.snb.2017.08.057 Document Version Accepted author manuscript Link to publication record in Manchester Research Explorer Citation for published version (APA): Chang, J-E., Lee, D-S., Ban, S-W., Oh, J., Jung, M. Y., Kim, S-H., Park, S., Persaud, K., & Jheon, S. (2017). Analysis of volatile organic compounds in exhaled breath for lung cancer diagnosis using a sensor system. Sensors and Actuators B: Chemical: international journal devoted to research and development of physical and chemical transducers, 255(1), 800-807. https://doi.org/10.1016/j.snb.2017.08.057 Published in: Sensors and Actuators B: Chemical: international journal devoted to research and development of physical and chemical transducers Citing this paper Please note that where the full-text provided on Manchester Research Explorer is the Author Accepted Manuscript or Proof version this may differ from the final Published version. If citing, it is advised that you check and use the publisher's definitive version. General rights Copyright and moral rights for the publications made accessible in the Research Explorer are retained by the authors and/or other copyright owners and it is a condition of accessing publications that users recognise and abide by the legal requirements associated with these rights. Takedown policy If you believe that this document breaches copyright please refer to the University of Manchester’s Takedown Procedures [http://man.ac.uk/04Y6Bo] or contact [email protected] providing relevant details, so we can investigate your claim.
    [Show full text]
  • Synthetic Turf Scientific Advisory Panel Meeting Materials
    California Environmental Protection Agency Office of Environmental Health Hazard Assessment Synthetic Turf Study Synthetic Turf Scientific Advisory Panel Meeting May 31, 2019 MEETING MATERIALS THIS PAGE LEFT BLANK INTENTIONALLY Office of Environmental Health Hazard Assessment California Environmental Protection Agency Agenda Synthetic Turf Scientific Advisory Panel Meeting May 31, 2019, 9:30 a.m. – 4:00 p.m. 1001 I Street, CalEPA Headquarters Building, Sacramento Byron Sher Auditorium The agenda for this meeting is given below. The order of items on the agenda is provided for general reference only. The order in which items are taken up by the Panel is subject to change. 1. Welcome and Opening Remarks 2. Synthetic Turf and Playground Studies Overview 4. Synthetic Turf Field Exposure Model Exposure Equations Exposure Parameters 3. Non-Targeted Chemical Analysis Volatile Organics on Synthetic Turf Fields Non-Polar Organics Constituents in Crumb Rubber Polar Organic Constituents in Crumb Rubber 5. Public Comments: For members of the public attending in-person: Comments will be limited to three minutes per commenter. For members of the public attending via the internet: Comments may be sent via email to [email protected]. Email comments will be read aloud, up to three minutes each, by staff of OEHHA during the public comment period, as time allows. 6. Further Panel Discussion and Closing Remarks 7. Wrap Up and Adjournment Agenda Synthetic Turf Advisory Panel Meeting May 31, 2019 THIS PAGE LEFT BLANK INTENTIONALLY Office of Environmental Health Hazard Assessment California Environmental Protection Agency DRAFT for Discussion at May 2019 SAP Meeting. Table of Contents Synthetic Turf and Playground Studies Overview May 2019 Update .....
    [Show full text]
  • Long-Term Effect of CFTR Modulator Therapy on Airway Nitric Oxide
    AGORA | RESEARCH LETTER Long-term effect of CFTR modulator therapy on airway nitric oxide To the Editor: The fraction of exhaled nitric oxide (FeNO) is generally lower in individuals with cystic fibrosis (CF), compared to healthy controls. Two recent studies reported that the cystic fibrosis transmembrane ’ conductance regulator (CFTR) potentiator ivacaftor resulted in an increase in FeNO after 4 weeks therapy [1, 2], suggesting that changes in FeNO have the potential to serve as biomarker of restored CFTR function. However, it is currently unknown whether ivacaftor results in a sustained increase in FeNO and whether combination therapy of ivacaftor with the CFTR corrector lumacaftor also leads to changes in FeNO. Therefore, the objective of this research was to document long-term effects of ivacaftor and lumacaftor– ivacaftor therapy on FeNO in treated CF patients. The two prospective observational studies were approved by the local institutional review boards (Hospital for Sick Children’s research ethics board #1000036224 and #1000057599, St Michael’s Hospital research ethics board #13-089). Patients were included if they had a confirmed diagnosis of CF and were eligible for treatment with either therapy. FeNO was measured before and 1, 3, 6, 12 and 24 months after initiation of therapy during regular outpatient visits. Sputum samples were collected in the ivacaftor cohort. The nonliquid phase (mucus plugs) of the sputum was processed by adding 0.1% dithiothreitol in Dulbecco’s PBS (4:1, vol:wt), and the clear supernatant of the cell suspension was separated from the cells by centrifugation [3, 4]. No protease inhibitors were added. Samples were stored at −80°C before analysis of L-arginine metabolism using liquid chromatography-mass spectrometry (LC-MS), as reported [5].
    [Show full text]
  • Orkambi, INN-Lumacaftor & Ivacaftor
    ANNEX I SUMMARY OF PRODUCT CHARACTERISTICS 1 This medicinal product is subject to additional monitoring. This will allow quick identification of new safety information. Healthcare professionals are asked to report any suspected adverse reactions. See section 4.8 for how to report adverse reactions. 1. NAME OF THE MEDICINAL PRODUCT Orkambi 100 mg/125 mg film-coated tablets Orkambi 200 mg/125 mg film-coated tablets 2. QUALITATIVE AND QUANTITATIVE COMPOSITION Orkambi 100 mg/125 mg film-coated tablets Each film-coated tablet contains 100 mg of lumacaftor and 125 mg of ivacaftor. Orkambi 200 mg/125 mg film-coated tablets Each film-coated tablet contains 200 mg of lumacaftor and 125 mg of ivacaftor. For the full list of excipients, see section 6.1. 3. PHARMACEUTICAL FORM Film-coated tablet (tablet) Orkambi 100 mg/125 mg film-coated tablets Pink, oval-shaped tablets (dimensions 14 × 7.6 × 4.9 mm) printed with “1V125” in black ink on one side. Orkambi 200 mg/125 mg film-coated tablets Pink, oval-shaped tablets (dimensions 14 × 8.4 × 6.8 mm) printed with “2V125” in black ink on one side. 4. CLINICAL PARTICULARS 4.1 Therapeutic indications Orkambi tablets are indicated for the treatment of cystic fibrosis (CF) in patients aged 6 years and older who are homozygous for the F508del mutation in the cystic fibrosis transmembrane conductance regulator (CFTR) gene (see sections 4.2, 4.4 and 5.1). 4.2 Posology and method of administration Orkambi should only be prescribed by physicians with experience in the treatment of CF. If the patient’s genotype is unknown, an accurate and validated genotyping method should be performed to confirm the presence of the F508del mutation on both alleles of the CFTR gene.
    [Show full text]
  • Arxiv:0801.0028V1 [Physics.Atom-Ph] 29 Dec 2007 § ‡ † (People’S China Metrology, Of) of Lic Institute Canada National Council, Zhang, Research Z
    CODATA Recommended Values of the Fundamental Physical Constants: 2006∗ Peter J. Mohr†, Barry N. Taylor‡, and David B. Newell§, National Institute of Standards and Technology, Gaithersburg, Maryland 20899-8420, USA (Dated: March 29, 2012) This paper gives the 2006 self-consistent set of values of the basic constants and conversion factors of physics and chemistry recommended by the Committee on Data for Science and Technology (CODATA) for international use. Further, it describes in detail the adjustment of the values of the constants, including the selection of the final set of input data based on the results of least-squares analyses. The 2006 adjustment takes into account the data considered in the 2002 adjustment as well as the data that became available between 31 December 2002, the closing date of that adjustment, and 31 December 2006, the closing date of the new adjustment. The new data have led to a significant reduction in the uncertainties of many recommended values. The 2006 set replaces the previously recommended 2002 CODATA set and may also be found on the World Wide Web at physics.nist.gov/constants. Contents 3. Cyclotron resonance measurement of the electron relative atomic mass Ar(e) 8 Glossary 2 4. Atomic transition frequencies 8 1. Introduction 4 1. Hydrogen and deuterium transition frequencies, the 1. Background 4 Rydberg constant R∞, and the proton and deuteron charge radii R , R 8 2. Time variation of the constants 5 p d 1. Theory relevant to the Rydberg constant 9 3. Outline of paper 5 2. Experiments on hydrogen and deuterium 16 3.
    [Show full text]
  • ORKAMBI, Every 3 These Highlights Do Not Include All the Information Needed to Use Months During the First Year of Treatment, and Annually Thereafter
    HIGHLIGHTS OF PRESCRIBING INFORMATION transaminases and bilirubin before initiating ORKAMBI, every 3 These highlights do not include all the information needed to use months during the first year of treatment, and annually thereafter. For ORKAMBI safely and effectively. See full prescribing information for patients with a history of ALT, AST, or bilirubin elevations, more ORKAMBI. frequent monitoring should be considered. Interrupt dosing in patients with ALT or AST >5 x upper limit of normal (ULN), or ALT or AST ORKAMBI™ (lumacaftor/ivacaftor) tablets, for oral use >3 x ULN with bilirubin >2 x ULN. Following resolution, consider the Initial U.S. Approval: 2015 benefits and risks of resuming dosing. (5 2, 6.1) • Respiratory events: Chest discomfort, dyspnea, and respiration abnormal ----------------------------INDICATIONS AND USAGE--------------------------- were observed more commonly during initiation of ORKAMBI. Clinical ORKAMBI is a combination of lumacaftor and ivacaftor, a cystic fibrosis experience in patients with percent predicted FEV1 (ppFEV1) <40 is transmembrane conductance regulator (CFTR) potentiator, indicated for the limited, and additional monitoring of these patients is recommended treatment of cystic fibrosis (CF) in patients age 12 years and older who are during initiation of therapy. (5.3, 6.1) homozygous for the F508del mutation in the CFTR gene. If the patient’s • Drug interactions: Use with sensitive CYP3A substrates or CYP3A genotype is unknown, an FDA-cleared CF mutation test should be used to detect substrates with a narrow therapeutic index may decrease systemic the presence of the F508del mutation on both alleles of the CFTR gene. (1) exposure of the medicinal products and co-administration is not recommended.
    [Show full text]
  • NMR Chemical Shifts of Common Laboratory Solvents As Trace Impurities
    7512 J. Org. Chem. 1997, 62, 7512-7515 NMR Chemical Shifts of Common Laboratory Solvents as Trace Impurities Hugo E. Gottlieb,* Vadim Kotlyar, and Abraham Nudelman* Department of Chemistry, Bar-Ilan University, Ramat-Gan 52900, Israel Received June 27, 1997 In the course of the routine use of NMR as an aid for organic chemistry, a day-to-day problem is the identifica- tion of signals deriving from common contaminants (water, solvents, stabilizers, oils) in less-than-analyti- cally-pure samples. This data may be available in the literature, but the time involved in searching for it may be considerable. Another issue is the concentration dependence of chemical shifts (especially 1H); results obtained two or three decades ago usually refer to much Figure 1. Chemical shift of HDO as a function of tempera- more concentrated samples, and run at lower magnetic ture. fields, than today’s practice. 1 13 We therefore decided to collect H and C chemical dependent (vide infra). Also, any potential hydrogen- shifts of what are, in our experience, the most popular bond acceptor will tend to shift the water signal down- “extra peaks” in a variety of commonly used NMR field; this is particularly true for nonpolar solvents. In solvents, in the hope that this will be of assistance to contrast, in e.g. DMSO the water is already strongly the practicing chemist. hydrogen-bonded to the solvent, and solutes have only a negligible effect on its chemical shift. This is also true Experimental Section for D2O; the chemical shift of the residual HDO is very NMR spectra were taken in a Bruker DPX-300 instrument temperature-dependent (vide infra) but, maybe counter- (300.1 and 75.5 MHz for 1H and 13C, respectively).
    [Show full text]
  • Breath Biomarker for Clinical Diagnosis and Different Analysis Technique
    ISSN: 0975-8585 Research Journal of Pharmaceutical, Biological and Chemical Sciences Breath biomarker for clinical diagnosis and different analysis technique Jessy Shaji*, Digambar Jadhav. Pharmaceutics Department, Prin. K. M. Kundnani College of Pharmacy, 23, Jote Joy Building, Rambhau Salgaokar Marg, Colaba, Mumbai – 400005. INDIA. ABSTRACT Disease detection by medical diagnosis has developed rapidly in recent years. Blood and urine are most commonly used in diagnosis as compared to breath. In contrast to blood and urine, breath analysis is easy, specific and highly qualitative. Breath analysis is intended for diagnosis of clinical manifestations of airway inflammations, metabolic disorders and gastroenteric diseases. Breath had analysis by new high quality technical instrument. It’s analytical results are qualitative and quantitative as compared to analysis of blood and urine. Mostly Gas Chromatography used in breath analysis with different detectors. Other techniques can also be satisfactorily used in the analysis of breath. This review is describes the breath biomarker use in different disease diagnosis with the help of various analytical technique. Keyword: Volatile organic compound, Disease, Diagnosis, Gas Chromatography *Corresponding author Email:[email protected] July – September 2010 RJPBCS Volume 1 Issue 3 Page No. 639 ISSN: 0975-8585 INTRODUCTION Breath analysis is a method to analyze exhaled air from animal or human being. It is used for clinical diagnosis, disease state and exposure to environmental conditions. The exhaled air contains volatile compounds at a concentration related to the blood concentrations. Nearly 200 compounds can be detected in human breath and it is correlated to various diseases. The actual breath contains mixtures of oxygen, carbon dioxide, water vapor, nitrogen, inert gases, in addition may also contain various elements and more than 1000 trace volatile compounds.
    [Show full text]
  • Accuracy and Methodologic Challenges of Volatile Organic Compound–Based Exhaled Breath Tests for Cancer Diagnosis: a Systematic Review and Pooled Analysis
    1 Supplementary Online Content Hanna GB, Boshier PR, Markar SR, Romano A. Accuracy and Methodologic Challenges of Volatile Organic Compound–Based Exhaled Breath Tests for Cancer Diagnosis: A Systematic Review and Pooled Analysis. JAMA Oncol. Published online August 16, 2018. doi:10.1001/jamaoncol.2018.2815 Supplement. eTable 1. Search strategy for cancer systematic review eTable 2. Modification of QUADAS-2 assessment tools eTable 3. QUADAS-2 results eTable 6. STARD assessment of each study eTable 7. Summary of factors reported to influence levels of volatile organic compounds within exhaled breath eFigure 1. Risk of bias and applicability concerns using QUADAS-2 eFigure 2. PRISMA flowchart of literature search eTable 4. Details of studies on exhaled volatile organic compounds in cancer eTable 5. Cancer VOCs in exhaled breath and their chemical class. eFigure 3. Chemical classes of VOCs reported in different tumor sites. This supplementary material has been provided by the authors to give readers additional information about their work. © 2018 American Medical Association. All rights reserved. Downloaded From: https://jamanetwork.com/ on 10/01/2021 2 eTable 1. Search strategy for cancer systematic review # Search 1 (cancer or neoplasm* or malignancy).ab. 2 limit 1 to abstracts 3 limit 2 to cochrane library [Limit not valid in Ovid MEDLINE(R),Ovid MEDLINE(R) Daily Update,Ovid MEDLINE(R) In-Process,Ovid MEDLINE(R) Publisher; records were retained] 4 limit 3 to english language 5 limit 4 to human 6 limit 5 to yr="2000 -Current" 7 limit 6 to humans 8 (cancer or neoplasm* or malignancy).ti. 9 limit 8 to abstracts 10 limit 9 to cochrane library [Limit not valid in Ovid MEDLINE(R),Ovid MEDLINE(R) Daily Update,Ovid MEDLINE(R) In-Process,Ovid MEDLINE(R) Publisher; records were retained] 11 limit 10 to english language 12 limit 11 to human 13 limit 12 to yr="2000 -Current" 14 limit 13 to humans 15 7 or 14 16 (volatile organic compound* or VOC* or Breath or Exhaled).ab.
    [Show full text]
  • Electronic Nose for Analysis of Volatile Organic Compounds in Air and Exhaled Breath
    University of Louisville ThinkIR: The University of Louisville's Institutional Repository Electronic Theses and Dissertations 5-2017 Electronic nose for analysis of volatile organic compounds in air and exhaled breath. Zhenzhen Xie University of Louisville Follow this and additional works at: https://ir.library.louisville.edu/etd Part of the Engineering Commons Recommended Citation Xie, Zhenzhen, "Electronic nose for analysis of volatile organic compounds in air and exhaled breath." (2017). Electronic Theses and Dissertations. Paper 2707. https://doi.org/10.18297/etd/2707 This Doctoral Dissertation is brought to you for free and open access by ThinkIR: The University of Louisville's Institutional Repository. It has been accepted for inclusion in Electronic Theses and Dissertations by an authorized administrator of ThinkIR: The University of Louisville's Institutional Repository. This title appears here courtesy of the author, who has retained all other copyrights. For more information, please contact [email protected]. ELECTRONIC NOSE FOR ANALYSIS OF VOLATILE ORGANIC COMPOUNDS IN AIR AND EXHALED BREATH By Zhenzhen Xie M.S., University of Louisville, 2013 B.S., Heilongjiang University, 2011 A Dissertation Submitted to the Faculty of the J. B. Speed School of Engineering University of Louisville in Partial Fulfillment of the Requirements for the Degree of Doctor of Philosophy in Chemical Engineering Department of Chemical Engineering Louisville, KY May 2017 ELECTRONIC NOSE FOR ANALYSIS OF VOLATILE ORGANIC COMPOUNDS IN AIR AND EXHALED BREATH by Zhenzhen Xie B.S., Heilongjiang University, 2011 M.S., University of Louisville, 2013 A Dissertation Approved On 04/03/2017 by the Following Committee: ___________________________________ Dr. Xiao-An Fu, Dissertation Director ___________________________________ Dr.
    [Show full text]